• 목록
• 답변
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD face a difficult decision on whether to keep or stop taking ADHD medication during pregnancy and breastfeeding. There are few data on how long-term exposure may affect a pregnant fetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus don't develop neurological conditions like impaired vision or hearing, febrile seizures, or IQ impairment. The authors acknowledge the need for more high-quality studies.

Risk/Benefit Analysis

Pregnant women who take ADHD medications must weigh the benefits of taking them against the potential risks to the foetus. The doctors don't have the information to give clear advice but they can provide information about risks and benefits to help pregnant women make informed choices.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during early pregnancy were not at a greater risk of fetal malformations, or structural birth defects. Researchers conducted a large population-based study of case-control to assess the risk of major structural birth defects in babies born to mothers who had taken stimulants during the early stages of pregnancy, as well as those who had not. Pediatric cardiologists, clinical geneticists and other experts examined the cases to confirm that the classification was accurate and to minimize any bias.

The study of the researchers was not without limitations. The researchers were not able in the beginning to differentiate the effects triggered by the medication from the disorder. This makes it difficult for researchers to determine if the small associations observed among the groups exposed were due to the use of medications, or if they were caused by the presence of comorbidities. The researchers also did not examine long-term outcomes for the offspring.

The study did show that infants whose mothers took ADHD medications during pregnancy were at a slightly greater risk of being admitted to the neonatal intensive care unit (NICU) than infants who were born without any medication or stopped their medications before or during pregnancy. The reason for this was central nervous system-related disorders, and the increased risk of admission did not appear to be affected by the type of stimulant medications were used during pregnancy.

Women who were taking stimulant ADHD medication during pregnancy were also at an increased chance of having a caesarean section or having a baby born with low Apgar score (less than 7). These increases appear to be independent of the type of medication taken during pregnancy.

The researchers suggest that the low risk associated with the use of ADHD medications during the early stages of pregnancy could be offset by the higher benefit to both the mother and child from continued treatment for the woman's condition. Physicians should discuss this with their patients and, when possible, assist them in developing strategies for improving their coping skills that can lessen the effects of her disorder on her daily functioning and relationships.

Medication Interactions

As more women than ever are diagnosed with adhd medication Pregnancy and treated with medication, the issue of whether or not to discontinue treatment during pregnancy is one that more and more doctors face. These decisions are usually made without clear and reliable evidence. Instead, doctors have to consider their own expertise and experience, as well as the experiences of other doctors and the research on the topic.

The issue of risk to the infant can be particularly tricky. The research on this subject is based on observation rather than controlled studies and a lot of the results are in conflict. In addition, most studies limit their analysis to live births, which may underestimate severe teratogenic effects that lead to abortion or termination of the pregnancy. The study discussed in the journal club addresses these shortcomings, by examining both the data from deceased and live births.

Conclusion Some studies have found an association between ADHD medications and certain birth defects, other studies have not found a correlation. Most studies have shown an unintended, or slight negative impact. In the end, a careful risk/benefit analysis is required in every case.

For a lot of women with ADHD, the decision to discontinue medication can be difficult, if not impossible. In a recent article published in the Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can lead to depression and feelings of loneliness. In addition, a decrease in medication can interfere with the ability to perform work-related tasks and safely drive, which adhd medication is the best are important aspects of daily life for many people with ADHD.

She suggests that women who are not sure whether to take the medication or discontinue it due to pregnancy educate family members, colleagues, and friends about the condition, its effects on daily functioning, and the benefits of keeping the current treatment. In addition, educating them can help the woman feel supported as she struggles with her decision. It is important to note that certain medications can pass through the placenta, so if the patient decides to stop her ADHD medication during pregnancy and breastfeeding, she should be aware that traces of the medication could be transferred to the infant.

Risk of Birth Defects

As the use and misuse of adhd medication weight loss uk medications to treat the symptoms of attention deficit hyperactivity disorder (ADHD), increases as does the concern about the possible effects of the drugs on fetuses. A study that was published in the journal Molecular Psychiatry adds to the existing information on this topic. Utilizing two huge data sets researchers were able examine more than 4.3 million pregnancies and see whether the use of stimulant medications increased the risk of birth defects. Although the risk overall is low, the researchers did find that first-trimester exposure to ADHD medications was linked to a slightly higher rate of specific heart defects, such as ventriculoseptal defect (VSD).

The authors of the study did not discover any connection between early use of medication and congenital anomalies like facial deformities or club feet. The results are in agreement with previous studies that have shown a small, but significant increase in cardiac malformations for women who began taking ADHD medication prior to the time of the time of pregnancy. The risk increased in the latter part of pregnancy when many women began to stop taking their medication.

Women who used ADHD medications during the first trimester of their pregnancy were also more likely to have a caesarean section, a low Apgar score after delivery and a baby who required breathing assistance during birth. The researchers of the study were not able to remove bias in selection since they restricted the study to women who did not have any other medical conditions that might have contributed to the findings.

Researchers hope their research will provide doctors with information when they see pregnant women. They recommend that, while a discussion of the risks and benefits is crucial but the decision to stop or maintain treatment should be based on each woman's requirements and the severity of her ADHD symptoms.

The authors also warn that while discontinuing the medications is an option, it isn't an option to consider due to the high prevalence of depression and other mental health problems among women who are pregnant or who are recently post-partum. Further, research shows that women who stop taking their medications will have a harder adjustment to life without them after the baby is born.

Nursing

It can be overwhelming to become a mother. Women who suffer from ADHD may face a lot of challenges when they must manage their symptoms, attend doctor appointments, prepare for the birth of their child and adjust to a new routine. Many women decide to continue taking their ADHD medication during pregnancy.

The majority of stimulant medications are absorbed through breast milk in very small quantities, so the risk for breastfeeding infant is minimal. The rate of medication exposure will vary based on the dosage the medication is administered, its frequency and the time of day. Additionally, different medications enter the body of the baby differently through the gastrointestinal tract and breast milk. The impact of this on a newborn is not fully understood.

Because of the lack of evidence, some doctors might be tempted to stop taking stimulant drugs during the pregnancy of a woman. It is a difficult decision for the mother, who must weigh the advantages of taking her medication as well as the risk to the embryo. Until more information is available, doctors should ask all pregnant patients about their experience with ADHD and if they are taking or planning to take medication during the perinatal period.

A increasing number of studies have proven that most women can safely continue taking their ADHD medication during pregnancy and breastfeeding. In response, a rising number of patients are choosing to do so. They have concluded, in consultation with their physicians that the benefits of continuing their current medication outweigh potential risks.

It is essential for women with ADHD who are thinking of breastfeeding to seek a specialist psychiatrist's guidance prior to becoming pregnant. They should discuss the medication they are taking with their physician, and the pros and cons for continuing treatment. This includes non-pharmacological strategies. Psychoeducation is also needed to help pregnant women with adhd focus medication understand the symptoms and underlying disorder. They should also be informed about treatment options and reinforce coping mechanisms. This should include an approach that is multidisciplinary, including the GP as well as obstetricians, psychiatry and obstetricians. Pregnancy counseling should include a discussion of a treatment plan for the mother and child, and monitoring for signs of deterioration, and, if necessary, adjustments to the medication regimen.